Novozymes CFO: By-products and higher prices elevate bioenergy
A great continuance, says CFO, waiving concerns over dwindling bioethanol production output on main US market.
VIKTOR BRANDT KÆRGAARD, TRANSLATED BY SIMON ØST VEJBÆK
Sequels rarely compares to originals when talking Hollywood movies. There are, however, a few exceptions. Godfather II springs to mind, as does The Two Towers, Terminator 2, and Q1 of 2023 for the Bioenergy division at Novozymes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novozymes surges yet again on Bioenergy
For subscribers
.jpg&w=384&q=75){kind=logo}